Journal of Pathology and Translational Medicine

Jeong Whan Park

2 Articles

Transglutaminase 2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma: Min Jee Park, Hae Woon Baek, Ye-Young Rhee, Cheol Lee, Jeong Whan Park, Hwal Woong Kim, Kyung Chul Moon; J Pathol Transl Med. 2015;49(1):37-43. Published online January 15, 2015; DOI: https://doi.org/10.4132/jptm.2014.10.25

8,756 View
68 Download
15 Web of Science
17 Crossref

Background
A few recent studies have demonstrated a possible role of transglutaminase 2 (TG2) in tumorigenesis or progression of renal cell carcinoma (RCC). The aim of this study was to examine TG2 expression and its clinicopathologic significance in a large number of human clear cell RCCs (CCRCCs). Methods: We analyzed 638 CCRCC patients who underwent partial or radical nephrectomy between 1995 and 2005. The expression of TG2 was determined by immunohistochemistry and categorized into four groups, according to staining intensity: negative (0), mild (1+), moderate (2+), and strong (3+). Results: TG2 staining intensity was negative in 8.5% of CCRCC (n=54), 1+ in 32.6% (n=208), 2+ in 50.5% (n=322), and 3+ in 8.5% (n=54). Strong TG2 expression was correlated with high Fuhrman nuclear grade (p=.011), high T category (p=.049), metastasis (p=.043) and male sex (p<.001) but not with N category.The survival analysis showed a significant association between strong TG2 expression and worse overall and cancer-specific survival (p=.027 and p=.010, respectively). On multivariate analysis, strong TG2 expression was a marginally significant prognostic indicator for Fuhrman nuclear grade and TNM staging (p=.054). Conclusions: Our study is the first to demonstrate the clinicopathologic significance of TG2 expression in a large number of human CCRCC samples. Strong TG2 expression was associated with high nuclear grade and poor prognosis.

Citations

Citations to this article as recorded by

Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma
Ga-Ram Kim, Joon Hee Kang, Hyeon Joo Kim, Eunji Im, Jinsu Bae, Woo Sun Kwon, Sun Young Rha, Hyun Cheol Chung, Eun Yi Cho, Soo-Youl Kim, Yong-Chul Kim
Bioorganic Chemistry.2024; 143: 107061. CrossRef
Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target
Patrizia Malkomes, Ilaria Lunger, Elsie Oppermann, Johannes Lorenz, Sara Fatima Faqar-Uz-Zaman, Jiaoyan Han, Sabrina Bothur, Paul Ziegler, Katrin Bankov, Peter Wild, Wolf Otto Bechstein, Michael A. Rieger
Cancer Gene Therapy.2023; 30(10): 1346. CrossRef
Transglutaminase Type 2-MITF axis regulates phenotype switching in skin cutaneous melanoma
Silvia Muccioli, Valentina Brillo, Tatiana Varanita, Federica Rossin, Elisabetta Zaltron, Angelo Velle, Giorgia Alessio, Beatrice Angi, Filippo Severin, Anna Tosi, Manuela D’Eletto, Luca Occhigrossi, Laura Falasca, Vanessa Checchetto, Roberto Ciaccio, Ame
Cell Death & Disease.2023;[Epub] CrossRef
The role of transglutaminase 2 in regulation of the balance between autophagy and apoptosis in tumor cells
Yu. A. Gnennaya, O. M. Semenov, N. A. Barlev
Advances in Molecular Oncology.2023; 10(4): 31. CrossRef
Application of a Fluorescence Anisotropy-Based Assay to Quantify Transglutaminase 2 Activity in Cell Lysates
Sandra Hauser, Paul Sommerfeld, Johanna Wodtke, Christoph Hauser, Paul Schlitterlau, Jens Pietzsch, Reik Löser, Markus Pietsch, Robert Wodtke
International Journal of Molecular Sciences.2022; 23(9): 4475. CrossRef
The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour Microenvironment
Robert Tempest, Sonia Guarnerio, Rawan Maani, Jamie Cooper, Nicholas Peake
Cancers.2021; 13(11): 2788. CrossRef
A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2
Soo-Youl Kim, Jeffrey W. Keillor
International Journal of Molecular Sciences.2020; 21(7): 2493. CrossRef
Evaluation of nuclear NF-κB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors
Alan A. Azambuja, Paula Engroff, Bruna T. Silva, Roberta C. S. Zorzetti, Fernanda B. Morrone
International braz j urol.2020; 46(3): 353. CrossRef
Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma
Seon-Hyeong Lee, Joon Hee Kang, Ji Sun Ha, Jae-Seon Lee, Su-Jin Oh, Hyun-Jung Choi, Jaewhan Song, Soo-Youl Kim
International Journal of Molecular Sciences.2020; 21(14): 5042. CrossRef
Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression
Burge Ulukan, Ajna Bihorac, Tarik Sipahioglu, Robert Kiraly, Laszlo Fesus, Dilek Telci
ACS Omega.2020; 5(43): 28273. CrossRef
Transglutaminase 2: The Maestro of the Oncogenic Mediators in Renal Cell Carcinoma
Ayca Ece Nezir, Burge Ulukan, Dilek Telci
Medical Sciences.2019; 7(2): 24. CrossRef
Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target
Richard L. Eckert
Molecular Carcinogenesis.2019; 58(6): 837. CrossRef
Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus
Nayeon Kim, Joon Hee Kang, Won-Kyu Lee, Seul-Gi Kim, Jae-Seon Lee, Seon-Hyeong Lee, Jong Bae Park, Kyung-Hee Kim, Young-Dae Gong, Kwang Yeon Hwang, Soo-Youl Kim
Amino Acids.2018; 50(11): 1583. CrossRef
Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition
Seon-Hyeong Lee, Won-Kyu Lee, Nayeon Kim, Joon Kang, Kyung-Hee Kim, Seul-Gi Kim, Jae-Seon Lee, Soohyun Lee, Jongkook Lee, Jungnam Joo, Woo Kwon, Sun Rha, Soo-Youl Kim
Cancers.2018; 10(11): 455. CrossRef
Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma
Yesim Bagatur, Ayca Zeynep Ilter Akulke, Ajna Bihorac, Merve Erdem, Dilek Telci
Cell Adhesion & Migration.2017; : 1. CrossRef
Characterization of clear cell renal cell carcinoma by gene expression profiling
Bryan J. Thibodeau, Matthew Fulton, Laura E. Fortier, Timothy J. Geddes, Barbara L. Pruetz, Samreen Ahmed, Amy Banes-Berceli, Ping L. Zhang, George D. Wilson, Jason Hafron
Urologic Oncology: Seminars and Original Investigations.2016; 34(4): 168.e1. CrossRef
Prognostic role of tissue transglutaminase 2 in colon carcinoma
María Jesús Fernández-Aceñero, Sofía Torres, Irene Garcia-Palmero, Cristina Díaz del Arco, J. Ignacio Casal
Virchows Archiv.2016; 469(6): 611. CrossRef

ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients: Cheol Lee, Jeong Whan Park, Ja Hee Suh, Kyung Han Nam, Kyung Chul Moon; Korean J Pathol. 2013;47(5):452-457. Published online October 25, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.5.452

7,215 View
57 Download
27 Crossref

Abstract PDF

Background

Recently, there have been a few reports of renal cell carcinoma (RCC) cases with anaplastic lymphoma kinase (ALK) gene fusion. In this study, we screened consecutively resected RCCs from a single institution for ALK protein expression by immunohistochemistry, and then we performed fluorescence in situ hybridization to confirm the ALK gene alteration in ALK immunohistochemistry-positive cases.

Methods

We screened 829 RCCs by ALK immunohistochemistry, and performed fluorescence in situ hybridization analysis using ALK dual-color break-apart rearrangement probe. Histological review and additional immunohistochemistry analyses were done in positive cases.

Results

One ALK-positive case was found. Initial diagnosis of this case was papillary RCC type 2. This comprises 0.12% of all RCCs (1/829) and 1.9% of papillary RCCs (1/53). This patient was a 44-year-old male with RCC found during routine health check-up. He was alive without evidence of disease 12 years after surgery. The tumor showed a papillary and tubular pattern, and showed positivity for CD10 (focal), epithelial membrane antigen, cytokeratin 7, pan-cytokeratin, PAX-2, and vimentin.

Conclusions

We found the first RCC case with ALK gene rearrangement in Korean patients by ALK immunohistochemistry among 829 RCCs. This case showed similar histological and immunohistochemical features to those of previous adult cases with ALK rearrangement, and showed relatively good prognosis.

Citations

Citations to this article as recorded by

Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
Giovanni Maria Iannantuono, Silvia Riondino, Stefano Sganga, Mario Roselli, Francesco Torino
International Journal of Molecular Sciences.2022; 23(7): 3995. CrossRef
Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia
Kiril Trpkov, Sean R. Williamson, Anthony J. Gill, Adebowale J. Adeniran, Abbas Agaimy, Reza Alaghehbandan, Mahul B. Amin, Pedram Argani, Ying-Bei Chen, Liang Cheng, Jonathan I. Epstein, John C. Cheville, Eva Comperat, Isabela Werneck da Cunha, Jennifer B
Modern Pathology.2021; 34(6): 1167. CrossRef
ESC, ALK, HOT and LOT: Three Letter Acronyms of Emerging Renal Entities Knocking on the Door of the WHO Classification
Farshid Siadat, Kiril Trpkov
Cancers.2020; 12(1): 168. CrossRef
ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology
Jen-Fan Hang, Hsiao-Jen Chung, Chin-Chen Pan
Virchows Archiv.2020; 476(6): 921. CrossRef
Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion
Chang Gok Woo, Seok Jung Yun, Seung-Myoung Son, Young Hyun Lim, Ok-Jun Lee
Yonsei Medical Journal.2020; 61(3): 262. CrossRef
Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers
Sean R. Williamson, Anthony J. Gill, Pedram Argani, Ying-Bei Chen, Lars Egevad, Glen Kristiansen, David J. Grignon, Ondrej Hes
American Journal of Surgical Pathology.2020; 44(7): e47. CrossRef
ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217
Naoto Kuroda, Kiril Trpkov, Yuan Gao, Maria Tretiakova, Yajuan J. Liu, Monika Ulamec, Kengo Takeuchi, Abbas Agaimy, Christopher Przybycin, Cristina Magi-Galluzzi, Soichiro Fushimi, Fumiyoshi Kojima, Malthide Sibony, Jen-Fan Hang, Chin-Chen Pan, Asli Yilma
Modern Pathology.2020; 33(12): 2564. CrossRef
ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma
Yiqi Zhu, Ning Liu, Wei Guo, Xiaohong Pu, Hongqian Guo, Weidong Gan, Dongmei Li
Pathology - Research and Practice.2020; 216(12): 153286. CrossRef
New and emerging renal entities: a perspective post‐WHO 2016 classification
Kiril Trpkov, Ondřej Hes
Histopathology.2019; 74(1): 31. CrossRef
Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics
Samer Nassif, Ziad M. El-Zaatari, Michel Attieh, Maya Hijazi, Najla Fakhreddin, Tarek Aridi, Fouad Boulos
Medicine.2019; 98(32): e16702. CrossRef
Targeted next-generation sequencing revealed distinct clinicopathologic and molecular features of VCL-ALK RCC: A unique case from an older patient without clinical evidence of sickle cell trait
Xiao-tong Wang, Ru Fang, Sheng-bing Ye, Ru-song Zhang, Rui Li, Xuan Wang, Rong-hao Ji, Zhen-feng Lu, Heng-hui Ma, Xiao-jun Zhou, Qiu-yuan Xia, Qiu Rao
Pathology - Research and Practice.2019; 215(11): 152651. CrossRef
ALK-rearranged renal cell carcinomas in Polish population
Adam Gorczynski, Piotr Czapiewski, Aleksandra Korwat, Lukasz Budynko, Monika Prelowska, Krzysztof Okon, Wojciech Biernat
Pathology - Research and Practice.2019; 215(12): 152669. CrossRef
ALK-TPM3 rearrangement in adult renal cell carcinoma: a case report and literature review
Jing Yang, Lei Dong, Hong Du, Xiu-bo Li, Yan-xiao Liang, Guo-rong Liu
Diagnostic Pathology.2019;[Epub] CrossRef
Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach
Reza Alaghehbandan, Delia Perez Montiel, Ana Silvia Luis, Ondrej Hes
Cancers.2019; 12(1): 85. CrossRef
ALK-TPM3 rearrangement in adult renal cell carcinoma: Report of a new case showing loss of chromosome 3 and literature review
Yohan Bodokh, Damien Ambrosetti, Valérie Kubiniek, Branwel Tibi, Matthieu Durand, Jean Amiel, Morgane Pertuit, Anne Barlier, Florence Pedeutour
Cancer Genetics.2018; 221: 31. CrossRef
Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma
Yong Jin Cho, Soo Hee Kim, Eun Kyung Kim, Jung Woo Han, Kyoo-Ho Shin, Hyuk Hu, Kyung Sik Kim, Young Deuk Choi, Sunghoon Kim, Young Han Lee, Jin-Suck Suh, Joong Bae Ahn, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha, Sung-Taek Jung, Hyo Song Kim
BMC Cancer.2018;[Epub] CrossRef
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma
Sumanta K. Pal, Paulo Bergerot, Nazli Dizman, Cristiane Bergerot, Jacob Adashek, Russell Madison, Jon H. Chung, Siraj M. Ali, Jeremy O. Jones, Ravi Salgia
European Urology.2018; 74(1): 124. CrossRef
Genetic analysis and clinicopathological features of ALK‐rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review
Wenjuan Yu, Yuewei Wang, Yanxia Jiang, Wei Zhang, Yujun Li
Histopathology.2017; 71(1): 53. CrossRef
A case of anaplastic lymphoma kinase‐positive renal cell carcinoma coincident with Hodgkin lymphoma
Yuzo Oyama, Haruto Nishida, Takahiro Kusaba, Hiroko Kadowaki, Motoki Arakane, Tsutomu Daa, Dai Watanabe, Yasuyuki Akita, Fuminori Sato, Hiromitsu Mimata, Shigeo Yokoyama
Pathology International.2017; 67(12): 626. CrossRef
Clinicopathologic and Molecular Pathology of Collecting Duct Carcinoma and Related Renal Cell Carcinomas
An Na Seo, Ghilsuk Yoon, Jae Y. Ro
Advances in Anatomic Pathology.2017; 24(2): 65. CrossRef
The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications
Soo Hee Kim, Woo Ick Yang, Yoo Hong Min, Young Hyeh Ko, Sun Och Yoon
Tumor Biology.2016; 37(2): 2037. CrossRef
New and emerging renal tumour entities
Naoto Kuroda, Ondřej Hess, Ming Zhou
Diagnostic Histopathology.2016; 22(2): 47. CrossRef
ALK‐rearranged renal cell carcinomas in children
Mariana M. Cajaiba, Lawrence J. Jennings, Stephen M. Rohan, Antonio R. Perez‐Atayde, Adrian Marino‐Enriquez, Jonathan A. Fletcher, James I. Geller, Katrin M. C. Leuer, Julia A. Bridge, Elizabeth J. Perlman
Genes, Chromosomes and Cancer.2016; 55(5): 442. CrossRef
Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene
Hironori Kusano, Yuki Togashi, Jun Akiba, Fukuko Moriya, Katsuyoshi Baba, Naomi Matsuzaki, Yoshiaki Yuba, Yusuke Shiraishi, Hiroshi Kanamaru, Naoto Kuroda, Seiji Sakata, Kengo Takeuchi, Hirohisa Yano
American Journal of Surgical Pathology.2016; 40(6): 761. CrossRef
Expanding the spectrum of ALK‐rearranged renal cell carcinomas in children: Identification of a novel HOOK1‐ALK fusion transcript
Mariana M. Cajaiba, Lawrence J. Jennings, David George, Elizabeth J. Perlman
Genes, Chromosomes and Cancer.2016; 55(10): 814. CrossRef
TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: Report of a case with a TPM3-ALK translocation
Paul Scott Thorner, Mary Shago, Paula Marrano, Furqan Shaikh, Gino R. Somers
Pathology - Research and Practice.2016; 212(10): 937. CrossRef
ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult
Marie Jeanneau, Valerie Gregoire, Claude Desplechain, Fabienne Escande, Dan Petre Tica, Sebastien Aubert, Xavier Leroy
Pathology - Research and Practice.2016; 212(11): 1064. CrossRef

Author index